Sage Therapeutics Stock Soars

Biogen Wants to Buy Its Partner Sage for Almost No Premium
Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01. Sage’s board will now review and evaluate the offer,
Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?
Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.
Sage Therapeutics Stock Headed for Best Day in 5 Years
Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from their Nov. 20 record low of $4.62, the shares are still down 72% year over year.
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.The bid of $7.22 per share was a 30% premium to Sage's closing price on Friday.
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share. As the first and only approved drug for post-partum depression,
Hold Rating for SAGE Therapeutics Amid Biogen Acquisition Offer and Pipeline Challenges
Morgan Stanley analyst Vikram Purohit has maintained their neutral stance on SAGE stock, giving a Hold rating on January 7.Stay Ahead of the
1SAGE, BIIB : Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy:...
Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.
SAGE Therapeutics Inc (SAGE) Stock: Understanding Its Underlying Value
RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed the stock to Mkt Perform.
BofA moves to No Rating on Sage Therapeutics after Biogen bid
BofA is moving to No Rating on Sage Therapeutics (SAGE) after the company announced it has received an unsolicited, nonbinding acquisition
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last?
Sage Therapeutics, Inc. (SAGE) shares soared 35.1% in the last trading session to close at $7.50. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from Analysts
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...
BioPharma Dive1d
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
FiercePharma2d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report). The ...
STAT1d
Biogen CEO confirms he’s shopping for biotechs: ‘We will be doing deals’
Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.
Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE) today announced that Chief Executive Officer Barry Greene will discuss the Company’s strategic focus areas for 2025 at the 43rd Annual J.P. Morgan Healthcare ...
Business Insider1d
Sage takeout bid implies zero enterprise value, says Mizuho
Mizuho analyst Uy Ear says that while Biogen’s (BIIB) offer for Sage Therapeutics (SAGE) is a 30% premium to Sage’s Friday’s closing price, which is attractive, the stock has been trading below ...